Colombia vs Equatorial Guinea: Average cost of multi drug-resistant tuberculosis treatment
Colombia
1,528 constant 2022 US$
in 2024
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Colombia rank
32nd
Equatorial Guinea rank
34th
Average cost of multi drug-resistant tuberculosis treatment over time
- Colombia
- Equatorial Guinea
How they compare
Colombia currently reports 1,528 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea, a difference of 28 constant 2022 US$.
The two have swapped places 4 times across 6 shared years of data; in 2019 it was Colombia ahead.
Colombia ranks 32nd and Equatorial Guinea ranks 34th of 92 countries.
Across the 2 decades both report, Colombia averaged higher in 1 and Equatorial Guinea in 1.
Head to head by decade
| Decade | Colombia | Equatorial Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,500 constant 2022 US$ | 1,000 constant 2022 US$ | 1,500 constant 2022 US$ | Colombia |
| 2020s | 953 constant 2022 US$ | 1,362 constant 2022 US$ | 409.2 constant 2022 US$ | Equatorial Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Colombia or Equatorial Guinea?
- Colombia, at 1,528 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Colombia and Equatorial Guinea?
- 28 constant 2022 US$, with Colombia ahead.
- How many years of comparable data are there for Colombia and Equatorial Guinea?
- 6 years are reported by both, from 2019 to 2024.
- How do Colombia and Equatorial Guinea rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Colombia ranks 32nd and Equatorial Guinea ranks 34th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.